Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies
- Inspira Technologies introduces a unique blood simulation capability to simulate human blood conditions without animal testing.
- The platform aids in advancing the development of the HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system.
- The technology allows for real-time monitoring of blood parameters, enhancing testing efficacy and accuracy in key scenarios.
- The capability may lead to faster research expansion, reduced costs, and improved resource utilization.
- The Chief Technology Officer emphasizes the focus on advanced blood monitoring and oxygen delivery technologies.
- Inspira Technologies aims to revolutionize respiratory treatment with its Augmented Respiration Technology (INSPIRA ART).
- None.
Insights
In light of Inspira Technologies' announcement regarding their in-house capability to simulate human blood conditions, the implications for the medical device industry are significant. The ability to mimic arterial and venous blood parameters circumvents the ethical and logistical complexities of in vivo animal testing. This could lead to a more streamlined research and development process for their HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system. The potential for reduced development time and cost is a key factor for stakeholders, as it may result in faster time-to-market for new technologies.
Furthermore, the high-end lab capabilities described enable the company to monitor and control a wide range of blood parameters. This is crucial for ensuring the efficacy and safety of medical devices, particularly those involved in critical care scenarios. By simulating acute medical conditions, Inspira Technologies can fine-tune their devices to address the specific needs of patients with compromised respiratory functions. The ability to test under extreme conditions without the need for animal testing could position Inspira Technologies favorably in the eyes of regulatory entities and the public.
The announcement by Inspira Technologies could hold considerable weight for investors and the stock market. The company's share price may respond to the potential for cost savings and increased efficiency in their R&D process. Investors typically value innovation, especially when it has the potential to disrupt existing markets, such as the mechanical ventilator market.
However, it's important to note that Inspira Technologies' products have not yet been tested or used in humans, nor have they been approved by regulatory entities. This represents a significant risk factor, as the journey from a promising technology to a marketable product can be fraught with unforeseen challenges and expenses. Investors should weigh the potential for high returns against the inherent risks associated with the development of medical technologies.
The respiratory treatment market is poised for growth, driven by an aging population and an increase in respiratory diseases. Inspira Technologies' entry with a novel Augmented Respiration Technology (INSPIRA ART) could capture a share of this expanding market. Their approach, which potentially allows patients to remain awake during treatment, offers a significant advantage over traditional mechanical ventilation systems that require intubation.
While this positions Inspira Technologies as a potential market disruptor, it's imperative to consider market readiness and the adoption curve for new medical technologies. The company's ability to meet regulatory standards and demonstrate not just clinical efficacy but also cost-effectiveness will be critical in gaining acceptance from healthcare providers and insurers. The reduction in development costs and improved verification and validation processes could facilitate a more aggressive pricing strategy, potentially accelerating market penetration.
RA'ANANA,
Using unique methods and equipment, our team of scientists has the ability to simulate human blood conditions based on a predefined medical profile. The proprietary setting allows the management of blood parameters continuously and in real-time for a range of blood flow rates in order to simulate a patient's oxygen-deficient and carbon dioxide-rich blood after it has flowed through body organs and tissues.
We believe that these break-through capabilities may enable us to further expand our research within a shorter timeframe and with a better use of resources, thereby reducing time and costs. The increased access to data is an important contributing factor towards efforts to accelerate the development, testing and release of new technologies and products as well as for more advanced verification and validation prior to regulatory submissions. This platform allows Inspira Technologies to control the blood parameters over a wide range, allowing it to test the efficacy and accuracy of its technologies in key scenarios, such as simulating the blood parameters of patients who may suffer from acute medical conditions. The Company's high-end lab capabilities include the means for monitoring oxygen and carbon dioxide levels and detecting hemolysis and other key parameters and elements under extreme conditions.
The Chief Technology Officer of Inspira Technologies, Dr. Daniella Yeheskely-Hayon, stated: "Inspira Technologies focuses on developing advanced blood monitoring and oxygen delivery technologies through its high-end testing platforms which allows it perform wider range-controlled testing while minimizing the need to perform in vivo animal testing."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-introduces-high-end-platform-for-bio-mimicking-blood-parameters-for-development-and-testing-of-core-technologies-302068715.html
SOURCE Inspira Technologies
FAQ
What is the name of the breakthrough medical technology company mentioned in the press release?
What is the ticker symbol for Inspira Technologies?
What are the core technologies of the Inspira ART500?
Who is the Chief Technology Officer of Inspira Technologies?
What is the focus of Inspira Technologies' high-end testing platforms?
What is the purpose of the blood simulation capability unveiled by Inspira Technologies?
What technology is designed to rebalance patient oxygen saturation levels?
What is the potential benefit of the INSPIRA ART technology?
